CLINICAL RESEARCH CENTER FOR OPIOID AND COCAINE ABUSE

阿片类药物和可卡因滥用临床研究中心

• 批准号: 3105357
• 负责人: THOMAS Richard KOSTEN
• 金额: $ 129.83万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-08-01 至 1996-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3105357
• 关键词: cocaine; drug abuse; drug addiction; opiate alkaloid

This center for Research on Substance Abuse includes a Core and eight major projects organized into three Divisions for medication development: 1. preclinical neurobiology, 2. human laboratory studies and 3. clinical trials. The Core has stimulated novel approaches to cocaine neurobiology and pharmacotherapy by coordinating research efforts across Psychiatry, Pharmacology, Nuclear Medicine and Laboratory Medicine. It has developed innovative research ideas into current Center proposals (e.g. buproprion pilot, cocaine cue reactivity, place preference in animals), as well as into projects that were later independently funded (e.g. HIV dementia, flupenthixol pilot, desipramine in methadone pilot). Core resources have also provided technical and material assistance in trainee' research projects that have led to independently funded research (e.g. mazindol pilot, amantadine pilot). Proposed pilot studies in the Core (e.g. disulfiram for alcoholic cocaine abusers, anxiety disorders and cocaine) should continue this tradition. Three of the eight major projects are continuations of our previous work: 1. the neurobiology of cocaine withdraw, 2. cocaine challenges during maintenance pharmacotherapies, 3. metabolic studies of cocaine focusing on the interaction of cocaine with alcohol. The other original Center projects have led to independently funded grants such as the three current buprenorphine studies, and no longer need Center funding. Five new projects evolved from Core pilot work: 1. animal models to screen medications and to understand the molecular mechanisms of cocaine's actions, 2. SPECT imaging of stimulant effects on dopamine neurobiology in primates and humans, 3. human laboratory studies of cocaine cue reactivity during neurotransmitter manipulation and during maintenance pharmacotherapy, and 4,5. clinical trials with buproprion and carbamazapine. Two new clinical sites have been added to increase the investigator and subject pools for studies: West Haven V.A. and the University of Connecticut. Thus, both continuity with our current Center and major new initiates towards a broad based medication development program have been incorporated into the continuation of our Research Center.

该药物滥用研究中心包括一个核心和八个 主要项目分为三个药物开发部门： 1.临床前神经生物学，2.人体实验室研究和3.临床 审判 核心刺激了可卡因神经生物学的新方法， 通过协调精神病学的研究工作， 药理学、核医学和实验室医学。 它发展了 当前中心提案中的创新研究理念（例如buproprion 飞行员，可卡因线索反应，动物的位置偏好），以及 后来独立资助的项目（例如艾滋病毒痴呆症， 氟哌噻吨先导试验、美沙酮先导试验中的地昔帕明）。 用核心资金 还为学员的研究提供技术和物质援助 导致独立资助研究的项目（如马吲哚 先导，金刚烷胺先导）。 拟议的核心区域试点研究（例如 用于可卡因滥用者、焦虑症和可卡因的双硫仑） 我们应该继续这一传统。 八个主要项目中有三个是我们以前工作的延续： 1.可卡因戒断的神经生物学，2.可卡因挑战 维持药物治疗，3.可卡因的代谢研究， 可卡因与酒精的相互作用 另一个原始中心 项目导致了独立资助的赠款，如三个目前的 丁丙诺啡研究，不再需要中心资助。 五个新 从核心试点工作演变而来的项目：1.筛选动物模型 了解可卡因的分子机制 行动，2.多巴胺神经生物学兴奋效应的SPECT显像 灵长类动物和人类，3。可卡因线索反应性的人体实验室研究 在神经递质操作和维护期间， 药物治疗和4.5。安非他酮的临床试验， 氨甲咪嗪 增加了两个新的临床研究中心， 研究的研究者和受试者汇总：West Haven V.A.和 康涅狄格大学。 因此，与我们目前的中心的连续性 和主要的新的开始走向一个广泛的基础药物开发 该计划已被纳入我们的研究的延续 中心